Products & Portfolio (4)
3 discontinued products not shown
OPVEE
nalmefene hydrochloride
Growth
NASAL · SPRAY
receptors.
depression
2023
0
PERSERIS KIT
risperidone
LOE Approaching
SUBCUTANEOUS · FOR SUSPENSION, EXTENDED RELEASE
risperidone, in schizophrenia, is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology ( )] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone.
schizophrenia in adultsschizophrenia
2018
15
SUBLOCADE
buprenorphine
Peak
SUBCUTANEOUS · SOLUTION, EXTENDED RELEASE
Partial Opioid Agonists
2017
0
SUBOXONE
buprenorphine hydrochloride, naloxone hydrochloride
Peak
BUCCAL, SUBLINGUAL · FILM
2010
8
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 7 approved products, 51 clinical trials
Top TAs: Neurology, Infectious Diseases, Gastroenterology
H-1B (2023): 1 approval
Portfolio Health
Growth1 (14%)
Peak2 (29%)
LOE Approaching4 (57%)
7 total products
Therapeutic Area Focus
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub